Publications by authors named "Jason Cross"

Claim this Profile
C
Characterization of the KRas G12D-inhibitor interactions by differential HDX-MS and molecular dynamics simulations.
Evgeniy V Petrotchenko, Brandon Novy, Edith Nagy, Konstantin I Popov, Jason B Cross

Comput Struct Biotechnol J· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Hit Prioritization Strategy for Compound Library Screening Using LiP-MS and Molecular Dynamics Simulations Applied to KRas G12D Inhibitors.
Foroughsadat Absar, Brandon Novy, Edith Nagy, Evgeniy V Petrotchenko, Konstantin I Popov, Jason B Cross

Anal Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric targeting of RIPK1: discovery of novel inhibitors parallel virtual screening and structure-guided optimization.
R S K Vijayan, Matthew M Hamilton, Dana E Pfaffinger, Fernando G Alvarez, Naphtali J Reyna, Jason B Cross

RSC Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity.
Xiuning Le, Jacqulyne P Robichaux, Monique Nilsson, R S K Vijayan, Ashwin Ravichandran, Jason B Cross

Nat Commun· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers.
Christopher L Carroll, Michael G Johnson, Yanbing Ding, Zhijun Kang, R S K Vijayan, Jason B Cross

J Med Chem· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing the workforce to deliver perioperative medicine for older people undergoing surgery: a transdisciplinary education programme.
Kar Yee Law, Jason Cross, Jugdeep Dhesi, Judith Partridge

Future Healthc J· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy.
Kang Le, Michael J Soth, Jason B Cross, Gang Liu, William J Ray

J Med Chem· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.
Yasir Y Elamin, Jacqulyne P Robichaux, Brett W Carter, Mehmet Altan, Hai Tran, Jason B Cross

Cancer Cell· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Screening of Hydrocarbon-Stapled Peptides for Inhibition of Calcium-Triggered Exocytosis.
Ying Lai, Michael J Tuvim, Jeremy Leitz, John Peters, Richard A Pfuetzner, Jason B Cross

Front Pharmacol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing preclinical drug discovery with artificial intelligence.
R S K Vijayan, Jan Kihlberg, Jason B Cross, Vasanthanathan Poongavanam

Drug Discov Today· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 6-[(3,4)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor.
Barbara Czako, Yuting Sun, Timothy McAfoos, Jason B Cross, Paul G Leonard

J Med Chem· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Jacqulyne P Robichaux, Xiuning Le, R S K Vijayan, J Kevin Hicks, Simon Heeke, Jason B Cross

Nature· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9779 and IACS-70465 as Potent Inhibitors Targeting Indoleamine 2,3-Dioxygenase 1 (IDO1) Apoenzyme.
Matthew M Hamilton, Faika Mseeh, Timothy J McAfoos, Paul G Leonard, Naphtali J Reyna, Jason B Cross

J Med Chem· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cork-in-bottle mechanism of inhibitor binding to mammalian complex I.
Injae Chung, Riccardo Serreli, Jason B Cross, M Emilia Di Francesco, Joseph R Marszalek

Sci Adv· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Yuting Sun, Brooke A Meyers, Barbara Czako, Paul Leonard, Faika Mseeh, Jason B Cross

Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R.
Barbara Czako, Joseph R Marszalek, Jason P Burke, Pijus Mandal, Paul G Leonard, Jason B Cross

J Med Chem· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Jason B Cross

Cancer Cell· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Jason B Cross

Cancer Cell· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The International Collaboration of Orthopaedic Nursing (ICON): Best practice nursing care standards for older adults with fragility hip fracture.
Anita J Meehan, Ann Butler Maher, Louise Brent, Panagiota Copanitsanou, Jason Cross

Int J Orthop Trauma Nurs· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Methods for Virtual Screening of GPCR Targets: Approaches and Challenges.
Jason B Cross

Methods Mol Biol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An inhibitor of oxidative phosphorylation exploits cancer vulnerability.
Jennifer R Molina, Yuting Sun, Marina Protopopova, Sonal Gera, Madhavi Bandi, Jason B Cross

Nat Med· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In-silico guided discovery of novel CCR9 antagonists.
Xin Zhang, Jason B Cross, Jan Romero, Alexander Heifetz, Eric Humphries

J Comput Aided Mol Des· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incorporating the American Pharmacists Association's Delivering Medication Therapy Management services certificate program into an accelerated pharmacy curriculum.
Jennifer L Donovan, Jason Cross, Amanda M Morrill, Paul P Belliveau, Cheryl A Abel

Curr Pharm Teach Learn· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-based discovery of LpxC inhibitors.
Jing Zhang, Audrey Chan, Blaise Lippa, Jason B Cross, Christopher Liu

Bioorg Med Chem Lett· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis